Feed NKTR
NK

Nektar Therapeutics

NKTR · NASDAQ

$67.10 -1.83% (-$1.25)
1M -9.35%
Market Cap $1.96B
P/E Ratio -
Div. Yield -
ROE 37.99%
Piotroski F-Score Weak
1/9
Valuation
42 /100
Fair
P/S 35.93x
P/B 2.17x
P/E N/A
Growth
0 /100
Declining
Rev. growth 15.66%
Book val. growth 37.43%
EPS growth N/A
Profitability
20 /100
Weak
Gross margin 99.36%
FCF margin 428.75%
Net margin 287.84%
Quality
1 /100
Poor
ROIC 12.54%
Asset turnover 0.05x
ROE 37.99%
Debt
69 /100
Low
Debt/Equity 0.15x
Int. coverage -4.36x
Current ratio 10.42x
Stability
45 /100
Moderate
Beta 1.15x
Profitable years 0
Rev. volatility 27.97%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about NKTR
Online

About the company

Nektar Therapeutics (NKTR) is an American biopharmaceutical company focused on researching, developing, and commercializing therapeutic agents for the treatment of cancer and other serious diseases. The company particularly focuses on innovative drugs utilizing its technologies to enhance drug bioavailability and pharmacokinetics. Their research and development efforts are aimed at treating various types of cancer, autoimmune diseases, and painful conditions. Nektar Therapeutics has a broad portfolio of drug candidates in development, both independently and in collaboration with other pharmaceutical companies. With successful approvals and commercialization of its products, Nektar Therapeutics is becoming a significant player in the field of innovative therapeutics. Shares of Nektar Therapeutics (NKTR) could be suitable for investors seeking opportunities in the biopharmaceutical sector with an emphasis on innovation and treatment of serious diseases.

Sector

Healthcare

Industry

Biotechnology

CEO

Howard W. Robin

Employees

63

Headquarters

San Francisco

Upcoming events

05 NOV

Earnings

Upcoming earnings report

46d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.